Abstract
Royal jelly is a food for queen and larvae honeybees. 10-Hydroxy-trans-2-decenoic acid (10H2DA; “royal jelly acid”) is the principal lipid component in royal jelly. Several pharmacological activities of 10H2DA have been reported: anti-tumor, anti-biotic, immunomodulatory, estrogenic and neurogenic. We recently revealed an inhibitory effect of 10H2DA in innate immune signals. Despite appreciable advances in studies on innate immune signals after the identification of Toll-like receptors as innate immune receptors, few studies have reported the effect of 10H2DA on innate immune signals. In this review, we focus on recent advances in the evaluation of the biological activities of 10H2DA (especially immunomodulatory activities). We also discuss the molecular mechanisms underpinning these biological activities, which could lead to new therapeutic targets for the treatment of immune disorders.
Keywords: Fatty acids, immune disorders, immunomodulator, innate immunity, royal jelly, Toll-like receptors, 10-Hydroxy-trans-2-decenoic acid (10H2DA; “royal jelly acid”), propolis, ω-hydroxy lipids, royal jelly protein (MRJP)1, nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), innate and adaptive immunity.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses
Volume: 12 Issue: 4
Author(s): Tsuyoshi Sugiyama, Keita Takahashi and Hiroshi Mori
Affiliation:
Keywords: Fatty acids, immune disorders, immunomodulator, innate immunity, royal jelly, Toll-like receptors, 10-Hydroxy-trans-2-decenoic acid (10H2DA; “royal jelly acid”), propolis, ω-hydroxy lipids, royal jelly protein (MRJP)1, nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), innate and adaptive immunity.
Abstract: Royal jelly is a food for queen and larvae honeybees. 10-Hydroxy-trans-2-decenoic acid (10H2DA; “royal jelly acid”) is the principal lipid component in royal jelly. Several pharmacological activities of 10H2DA have been reported: anti-tumor, anti-biotic, immunomodulatory, estrogenic and neurogenic. We recently revealed an inhibitory effect of 10H2DA in innate immune signals. Despite appreciable advances in studies on innate immune signals after the identification of Toll-like receptors as innate immune receptors, few studies have reported the effect of 10H2DA on innate immune signals. In this review, we focus on recent advances in the evaluation of the biological activities of 10H2DA (especially immunomodulatory activities). We also discuss the molecular mechanisms underpinning these biological activities, which could lead to new therapeutic targets for the treatment of immune disorders.
Export Options
About this article
Cite this article as:
Sugiyama Tsuyoshi, Takahashi Keita and Mori Hiroshi, Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses, Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (4) . https://dx.doi.org/10.2174/187153012803832530
DOI https://dx.doi.org/10.2174/187153012803832530 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications
Current Genomics Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Subject Index To Volume 13
Current Medicinal Chemistry The Common Mycobacterial Antigens and their Importance in the Treatment of Disease
Current Pharmaceutical Design Mesenchymal Stromal Cells Uptake and Release Paclitaxel without Reducing its Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Gemcitabine: A Critical Nucleoside for Cancer Therapy
Current Medicinal Chemistry Biomolecules of Human Female Fertility - Potential Therapeutic Targets for Pharmaceutical Design
Current Pharmaceutical Design The Role of Antihistamine Drugs in Allergic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents In Vivo Optical Imaging in Gene & Cell Therapy
Current Gene Therapy Targeting Heat Shock Proteins 70/90 and Proteasome for Cancer Therapy
Current Medicinal Chemistry Development of Anti-Atherosclerosis Therapy Based on the Inflammatory and Proliferative Aspects of the Disease
Current Pharmaceutical Design Neuroprotective Role of Natural Polyphenols
Current Topics in Medicinal Chemistry Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?
Current Gene Therapy The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology 5-Nitro-Thiophene-Thiosemicarbazone Derivatives Present Antitumor Activity Mediated by Apoptosis and DNA Intercalation
Current Topics in Medicinal Chemistry Germinated Soybean Products as Nutraceutical Compounds in Breadmaking
Current Nutrition & Food Science Natural Product Origins of Hsp90 Inhibitors
Current Cancer Drug Targets Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design Inflammatory Cytokines Pathways as Potential Therapeutic Targets for Gastric Cancer
Current Cancer Therapy Reviews